NICEATM–ICCVAM Participation

Sunday, August 21:

Satellite Meeting: Alternatives to the Pertussis Test
Time/Location: 12:00-5:00 p.m. – MacKenzie Room
NICEATM staff are attending the meeting

Monday, August 22:

Platform Session I-18: Report on the ICCVAM international workshop on vaccines
Time/Location: 12:45-2:00 p.m. – Joliette Room
Dr. William Stokes, NICEATM Director and ICCVAM Executive Director, is chairing the session
Invited Speakers include Dr. Richard McFarland, ICCVAM member, FDA/CBER, and Dr. Jodie Kulpa-Eddy, ICCVAM Chair and member, USDA

Platform Session I-7: Potency and safety testing of veterinary vaccines
Time/Location: 2:00-3:30 p.m. – Joliette Room
Presentation: Successful Development and Validation of an In Vitro Replacement Assay for Leptospira Potency Tests (J. Kulpa-Eddy, ICCVAM Chair and member, USDA)

Platform Session I-8: Safety testing for chemically-induced eye injuries: recent Three Rs advances
Time/Location: 2:00-3:30 p.m. – Duluth Room
Presentation: Development of a non-animal testing strategy for ocular hazard labeling of some specific EPA-regulated products (J. Fowle, ICCVAM member, U.S. EPA)

Platform Session II-1: Public accountability
Time/Location: 2:00-3:45 p.m. – Mackenzie Room
Dr. Suzanne Fitzpatrick, ICCVAM member, FDA/Office of the Commissioner, is a co-chair of the session
Tuesday, August 23:

**Poster Session I: Safety and Efficacy Testing of Chemicals, Pharmaceuticals and Biologicals**

**Time/Location:** 7:00 a.m.-3:15 p.m. – Hochelaga Room (4-6)

**Abstract I-11-575:** International Acceptance of the Nonradioactive LLNA: DA for Evaluating Allergic Contact Dermatitis Hazards  
**Authors:** P Brown, J Matheson, A Jacobs, R Ward, E Margosches, E Salicru, D Allen, F Stack, W Stokes

**Abstract I-11-574:** International Acceptance of the Nonradioactive LLNA: BrdU-ELISA for Evaluating Allergic Contact Dermatitis Hazards  
**Authors:** A Jacobs, J Matheson, V Malshet, J Toy, J Strickland, D Allen, T Burns, F Stack, W Stokes

**Abstract I-8-576:** Usefulness and Limitations of the Cytosensor Microphysiometer Test Method for Ocular Safety Testing  
**Authors:** W Stokes, D Lowther, A Layton, J Redden, E Lipscomb, J Truax, N Johnson, D Allen

**Abstract I-1-569:** International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Human Vaccine Potency and Safety Testing  
**Authors:** R McFarland, J Kulpa-Eddy, R Isbrucker, M Halder, H Kojima, D Verthelyi, M Schmitt, R Levis, N Johnson, B Jones, D Allen, W Casey, W Stokes

**Abstract I-1-570:** International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Veterinary Vaccine Potency and Safety Testing  
**Authors:** J Kulpa-Eddy, R McFarland, R Isbrucker, M Halder, H Kojima, G Srinivas, K Brown, B Jones, N Johnson, D Allen, W Casey, W Stokes

**Abstract I-11-567:** Evaluation of the Murine Local Lymph Node Assay (LLNA) for Potency Categorization of Chemicals Causing Allergic Contact Dermatitis in Humans  
**Authors:** J Strickland, P Brown, J Matheson, A Jacobs, T McMahon, D Germolec, D Allen, E Salicru, T Burns, F Stack, W Stokes

**Abstract I-11-568:** Evaluation of the Murine Local Lymph Node Assay (LLNA) for Assessing the Allergic Contact Dermatitis Hazard Potential of Pesticide Formulations  
**Authors:** T McMahon, D McCall, J Matheson, A Jacobs, T Burns, D Allen, W Stokes

**Abstract I-11-446:** Updated NICEATM Evaluation and International Acceptance of the Reduced Murine Local Lymph Node Assay  
**Authors:** D Allen, T Burns, J Strickland, E Salicru, and W Stokes

**Platform Session I-3:** Biological and biotechnology-based therapeutics
**Time/Location:** 9:45 a.m.-12:00 p.m. – Joliette Room

**Presentation:** Informal communication with US FDA: pre-preIND approach to reduction of animal use in translational research and product development (Y. Huang, ICCVAM member, FDA/CBER)

**Session I-4:** Validation and Three Rs strategies for assessment of endocrine-active substances

**Time/Location:** 9:45 a.m.-12:00 p.m. – Duluth Room

Dr. Warren Casey, NICEATM Deputy Director and ICCVAM member, NIEHS, is a co-chair of the session

**Presentation:** Use of Tox 21 Tools From Screening and Prioritization to Risk Assessment: When, How and What? (J. Fowle, ICCVAM member, EPA)

**Presentation:** BG1Luc ER TA test method: results of an international validation study and proposed performance standards (W. Casey, NICEATM Deputy Director/ICCVAM member, NIEHS)

**Session I-13:** Toxicity testing in the 21st century

**Time/Location:** 9:45 a.m.-4:00 p.m. – St. Francois Room

**Presentation:** Tox21: Activities of the National Toxicology Program/NIEHS (R. Tice, ICCVAM Interagency Genetic Toxicity Working Group member, NIEHS)
**Wednesday, August 24:**

**Poster Session IV:** Animal Welfare for Refinement and High Quality Science  
**Time/Location:** 7:00 a.m.-3:15 p.m. – Hochelaga Room (4-6)

**Abstract IV-1-292:** Eliminating Pain and Distress in Ocular Safety Testing: Use of Topical Anesthetics, Systemic Analgesics, and Humane Endpoints  
**Authors:** W Stokes, J Merrill, D Lowther, T McMahon, J Chen, M Hashim, M Lewis, B Jones, E Lipscomb, D Allen

**Session I-5:** Nanotechnology and the Three Rs  
**Time/Location:** 9:45 a.m.-12:00 p.m. – Joliette Room  
**Presentation:** Three Rs and the safety assessment of nanotech drugs (A. Jacobs, ICCVAM member, FDA/CDER)

**Session II-5:** Validation of Three Rs alternative methods  
**Time/Location:** 9:45 a.m.-12:00 p.m. – Mackenzie Room  
Dr. William Stokes, NICEATM Director and ICCVAM Executive Director, is a co-chair of the session  
**Presentation:** Validation of the 21st Century Toxicology Toolbox: Challenges, Opportunities, and the Way Forward (W. Stokes, NICEATM Director, ICCVAM Executive Director)

**Session V-7:** Relevance, Reproducibility and Robustness – the other Three Rs Important to science and animal welfare  
**Time/Location:** 9:45 a.m.-12:00 p.m. – St. Francois Room  
Dr. Myrtle Davis, ICCVAM Interagency Research and Development Working Group member, NCI, is a co-chair of the session

**Session I-17:** Update on new *in vitro* models for detection and potency assessment of botulinum neurotoxin  
**Time/Location:** 12:30-1:45 p.m. – Duluth Room  
Dr. Warren Casey, NICEATM Deputy Director and ICCVAM member, NIEHS, is a co-chair of the session

**Session II-11:** The International cooperation on alternative test methods (ICATM) (updates from the National Validation Centers)  
**Time/Location:** 3:15-4:15 p.m. – Duluth Room  
Dr. William Stokes, NICEATM Director and ICCVAM Executive Director, is chairing the session  
Dr. Stokes will also present an overview of NICEATM and ICCVAM and highlights of recent and planned ICATM contributions